Pacific Biosciences of Californi (NASDAQ: PACB) stock closed at $4.35 on 3/5/24 after a major decline of -10.9%. Moreover, unusually high trading volume at 168% of normal accompanied the decline. The stock has declined -16.8% during the last week and has been extremely weak relative to the market over the last nine months.
Current PriceTarget Research Rating
PACB’s future returns on capital are forecasted to be below the cost of capital. Accordingly, the company is expected to be a modest Value Eraser.
Pacific Biosciences of Californi has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Pacific Biosciences of Californi has a poor Appreciation Score of 20 and a very low Power Rating of 10, triggering the Lowest Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment